REX1BD

Across TCGA pan-cancer cohorts, REX1BD mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of REX1BD’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where REX1BD mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types REX1BD is over-expressed in tumor.

HNSC, LSCC, and CCRCC are the cancer types where REX1BD tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in REX1BD mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.544	.005	6	view →
LSCC	All	All	+0.300	<.001	4	view →
CCRCC	Male	All	+0.386	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

REX1BD–HNSC

Open the HNSC breakdown →